CJC-1295

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that has been structurally modified to extend its biological half-life through albumin binding. The 29-amino acid peptide retains the full biological activity of native GHRH(1-29) while the Drug Affinity Complex (DAC) modification provides sustained receptor activation.

The compound works by binding to and activating the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The albumin-binding DAC modification extends the plasma half-life from the native peptide's approximately 7 minutes to over 8 days, enabling sustained GH pulsatility.

Research has demonstrated that CJC-1295 produces dose-dependent increases in plasma GH and IGF-1 levels while maintaining the natural pulsatile pattern of GH release. This preservation of physiological secretion patterns makes it particularly valuable for research into GH/IGF-1 axis modulation.

CJC-1295 is frequently studied in combination with growth hormone releasing peptides (GHRPs) such as Ipamorelin, as the synergistic activation of both GHRH and GH secretagogue receptors produces amplified and more physiologically relevant GH responses.